Drug intelligence / Profile preview

Shubaile

Development stage: Unknown
Lead developer: Beijing Shuobai Pharmaceutical
Modality: Small Molecules
Administration: Intranasal

Overview

Shubaile (101BHG-D01) is a selective M3 muscarinic receptor antagonist developed as an intranasal spray for the treatment of chronic rhinitis. Developed by Beijing Shuobai Pharmaceutical Technology, the drug is designed to alleviate symptoms such as rhinorrhea and nasal congestion by blocking acetylcholine-mediated glandular secretion and vasodilation in the nasal passages. By specifically targeting the M3 receptor subtype, Shubaile aims to provide a more targeted therapeutic effect with a potentially improved safety profile compared to non-selective anticholinergic agents. It has been evaluated in Phase Ib/IIa clinical trials in China to assess its safety, tolerability, and preliminary efficacy in adult patients with chronic rhinitis.

Brand names: Shubaile

Targets

CHRM3 (M3)

Beyond the preview

Go deeper on Shubaile.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shubaile.

Explore the full profile